Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Atea Pharmaceuticals (Nasdaq: AVIR), a clinical-stage biopharmaceutical company focused on developing oral antiviral therapeutics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Jean-Pierre Sommadossi, PhD, the company's CEO and Founder, will deliver a business update presentation on Wednesday, January 15, 2025 at 5:15 p.m. PT in San Francisco.

The presentation will be accessible via live webcast on the company's investor relations website, with the recording remaining available for at least 90 days following the event.

BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will present a business update at the 43^rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 5:15 p.m. PT in San Francisco, CA.

A live webcast of the presentation will be available here and on the Company’s website at https://ir.ateapharma.com. An archived webcast will be available on Atea Pharmaceuticals’ website for at least 90 days following the event.

About Atea Pharmaceuticals

Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging Atea’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Our lead program and current focus is on the development of the combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, to treat HCV. For more information, please visit www.ateapharma.com.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to the anticipated date and time of the Company’s presentation at the conference. When used herein, words including “expects,” “may,” “will,” “anticipates,” “plans,” and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, the important factors discussed and updated from time to time under the caption “Risk Factors” in the reports the Company files with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other filings each of which are accessible on the SEC’s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

Contacts

Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
Barnes.jonae@ateapharma.com

Will O’Connor
Precision AQ
212-362-1200
will.oconnor@precisionaq.com

FAQ

When is Atea Pharmaceuticals (AVIR) presenting at the J.P. Morgan Healthcare Conference 2025?

Atea Pharmaceuticals (AVIR) is scheduled to present on Wednesday, January 15, 2025, at 5:15 p.m. PT in San Francisco.

How can investors watch AVIR's presentation at the J.P. Morgan Healthcare Conference?

Investors can watch the presentation through a live webcast available on Atea Pharmaceuticals' investor relations website at https://ir.ateapharma.com.

How long will AVIR's J.P. Morgan Healthcare Conference presentation recording be available?

The archived webcast will be available on Atea Pharmaceuticals' website for at least 90 days following the event.

What is the focus of AVIR's presentation at the 2025 J.P. Morgan Healthcare Conference?

The presentation will provide a business update from CEO and Founder Jean-Pierre Sommadossi, PhD, regarding the company's oral antiviral therapeutics development for serious viral diseases.